The changing scenario of non-Down syndrome acute megakaryoblastic leukemia in children.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.04.011
Abstract: Pediatric non-Down-syndrome acute megakaryoblastic leukemia (non-DS-AMKL) is a heterogeneous subtype of leukemia that has historically been associated with poor prognosis. Until the advent of large-scale genomic sequencing, the management of patients with non-DS-AMKL was very… read more here.
Keywords: non amkl; leukemia; syndrome acute; pediatric non ... See more keywords
Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18691
Abstract: Patients with acute megakaryoblastic leukaemia of Down syndrome (DS‐AMKL) have an excellent survival rate; however, patients with non‐DS‐AMKL experience poor outcomes. Therefore, this study retrospectively analysed 203 children with non‐DS‐AMKL who underwent their first haematopoietic… read more here.
Keywords: haematopoietic cell; non amkl; cell transplantation; acute megakaryoblastic ... See more keywords
Pediatric non–Down’s syndrome acute megakaryoblastic leukemia patients in China: A single center's real-world analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.940725
Abstract: Non-Down’s syndrome acute megakaryocytic leukemia (non-DS-AMKL) is a subtype of childhood acute myeloid leukemia (AML), whose prognosis, prognostic factors and treatment recommendations have not yet to be defined in children. We conducted a retrospective study… read more here.
Keywords: non syndrome; acute; non amkl; leukemia ... See more keywords
Clonal Myeloproliferative Disorders in Patients with Down Syndrome—Treatment and Outcome Results from an Institution in Argentina
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14133286
Abstract: Simple Summary Around 30% of children with Down Syndrome (DS) will develop Transient Abnormal Myelopoiesis (TAM) and 20% of them will progress to Acute Myeloid Leukemia (AML), mostly Megakaryoblastic Leukemia (AMKL). The optimal balance between… read more here.
Keywords: outcome; non amkl; leukemia; treatment related ... See more keywords